Longer gap in Pfizer-BioNTech COVID vaccines boosts antibody levels: Study – Devdiscourse

A longer gap between first and second doses of the Pfizer-BioNTech COVID-19 vaccine generates strong antibody and T cell immune responses, UK researchers have found.
The study, led by the University of Oxford, in collaboration with the Universities of Birmingham,…

Click here to view the original article.